Source: Eur Respir J, 51 (3) 1702369; 10.1183/13993003.02369-2017
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Jesse Armitage, Dino B.A. Tan, Russel Troedson, Paul Young, Kay-vin Lam, Kathryn Shaw, Marian Sturm, Daniel J. Weiss, Yuben P. Moodley. Mesenchymal stromal cell infusion modulates systemic immunological responses in stable COPD patients: a phase I pilot study. Eur Respir J, 51 (3) 1702369; 10.1183/13993003.02369-2017

Member's Comments

No comment yet.

Related content which might interest you: Systemic immunological changes following intravenous mesenchymal stromal cell infusion in stable COPD patients Source: International Congress 2018 – Novel immunology-based therapies in asthma and COPD Year: 2018 Effects of autologous mesenchymal stromal cell treatment for severe emphysema on lung tissue: A clinical trial Source: International Congress 2015 – The multiple facets of stem and progenitor cells in lung health and disease Year: 2015 A prospective, non randomized, clinical trial to study the safety and efficacy of the endobronchial autologous infusion of adipose-derived mesenchymal stem cells (ADMSCs) in patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2011 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2011 Mesenchymal stem cell therapy in a model of chronic inflammatory lung disease Source: International Congress 2019 – Cellular responses and cell therapy in lung injury and repair Year: 2019 Late Breaking Abstract - Mesenchymal stromal cell exosomes prevent and revert experimental pulmonary fibrosis through systemic modulation of monocyte phenotypes Source: International Congress 2018 – ILDs: From bench to bedside Year: 2018 Mesenchymal stem cell therapy reduces inflammation and damage in a model of chronic lung disease Source: ERS Lung Science Conference 2017 Year: 2017 Therapeutic potential of mesenchymal stem cells to attenuate immune cell tolerance in a late stage model of sepsis Source: Virtual Congress 2020 – Physiological and cellular mechanisms affecting pulmonary pathologies Year: 2020 Immunotherapeutic strategy with mesenchymal stem cells modulating inflammation in an experimental model of COPD. Source: Virtual Congress 2020 – New insight into the immunology of asthma and COPD Year: 2020 Late-breaking abstract: Comparison of bone marrow derived-mononuclear cells with mesenchymal stem cells on inflammatory and remodeling processes in experimental chronic allergic asthma Source: Annual Congress 2011 - Late-Breaking Abstracts Session: New mechanisms in airway disease Year: 2011 Prospective phase 1 open clinical trial to study the safety of adipose derived mesenchymal stem cells (ADMSCs) in COPD and combined pulmonary fibrosis and emphysema (CPFE) Source: International Congress 2015 – Notable abstracts in COPD: variety Year: 2015 Utility of bronchoscopy in hematopoietic stem cell transplant (HSCT) patients with pulmonary infiltrates: A prospective study. Source: Virtual Congress 2021 – Fungi, viruses, parasites and the immunocompromised Year: 2021 LSC 2010 Abstract: Does cigarette smoking influence bone marrow microenvironment? Down-regulation of CXCR4 expression in bone marrow-derived mesenchymal stem cells (BM-MSCs) in patients with chronic obstructive pulmonary disease (COPD): preliminary results Source: Annual Congress 2010 - Novel mechanisms in COPD Year: 2010 Late Breaking Abstract - High cumulative dose of allogeneic mesenchymal stem cells in patients with progressive idiopathic pulmonary fibrosis Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia Year: 2019 Both intranasal and intraperitoneal administration of human tubal mesenchymal stem cells (htMSC) ameliorates experimental COPD model Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014 Mesenchymal stromal cells in clinical trials: implications for emphysema Source: International Congress 2017 – Repair of the emphysematous lung: mesenchymal stromal cell and matrix interactions Year: 2017 Immunosuppressive properties of bronchial epithelial cells are altered in lung transplant recipients: “ex-vivo” model of T cell-allogeneic response Source: Annual Congress 2013 –New insights into mechanisms of lung allograft dysfunction Year: 2013 Functional comparison of bone-marrow derived mesenchymal stromal cells obtained from COPD patients and non-COPD controls Source: International Congress 2015 – Cellular and molecular mechanisms of COPD and emphysema Year: 2015 Mesenchymal stromal (stem) cell therapy modulates miR-193b-5p expression to attenuate sepsis-induced acute lung injury Source: Eur Respir J, 59 (1) 2004216; 10.1183/13993003.04216-2020 Year: 2022 Preclinical studies of mesenchymal stem cell (MSC) transplantation in chronic obstructive pulmonary disease (COPD): A systematic review and meta-analysis Source: International Congress 2016 – New signalling pathways in COPD Year: 2016 Circulating haemopoietic progenitors in COPD: effect of poor nutritional state Source: Eur Respir J 2007; 30: Suppl. 51, 446s Year: 2007